We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.14%. At the same time, the Dow lost 0.11%, and the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the drugmaker had gained 3.95% in the past month. In that same time, the Medical sector lost 3.51%, while the S&P 500 lost 0.91%.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be November 1, 2019. In that report, analysts expect ABBV to post earnings of $2.27 per share. This would mark year-over-year growth of 6.07%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.38 billion, up 1.78% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.93 per share and revenue of $33.05 billion. These results would represent year-over-year changes of +12.9% and +0.89%, respectively.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.1% higher. ABBV is currently a Zacks Rank #2 (Buy).
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 8.25. This represents a discount compared to its industry's average Forward P/E of 14.38.
It is also worth noting that ABBV currently has a PEG ratio of 1.5. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.08 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV - Free Report) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.14%. At the same time, the Dow lost 0.11%, and the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the drugmaker had gained 3.95% in the past month. In that same time, the Medical sector lost 3.51%, while the S&P 500 lost 0.91%.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be November 1, 2019. In that report, analysts expect ABBV to post earnings of $2.27 per share. This would mark year-over-year growth of 6.07%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.38 billion, up 1.78% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.93 per share and revenue of $33.05 billion. These results would represent year-over-year changes of +12.9% and +0.89%, respectively.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.1% higher. ABBV is currently a Zacks Rank #2 (Buy).
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 8.25. This represents a discount compared to its industry's average Forward P/E of 14.38.
It is also worth noting that ABBV currently has a PEG ratio of 1.5. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.08 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.